Sun Pharma Advanced Research Yönetim

Yönetim kriter kontrolleri 1/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Anilkumar Raghavan

İcra Kurulu Başkanı

₹69.6m

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	10.6yrs
CEO sahipliği	n/a
Yönetim ortalama görev süresi	1.2yrs
Yönetim Kurulu ortalama görev süresi	7.5yrs

Son yönetim güncellemeleri

Recent updates

Sun Pharma Advanced Research (NSE:SPARC) Is In A Good Position To Deliver On Growth Plans

Jan 17

Sun Pharma Advanced Research Company Limited's (NSE:SPARC) Business Is Trailing The Industry But Its Shares Aren't

Nov 14

Is Sun Pharma Advanced Research (NSE:SPARC) Using Too Much Debt?

Sep 05

Here's Why We're Not At All Concerned With Sun Pharma Advanced Research's (NSE:SPARC) Cash Burn Situation

Jun 27

Is Sun Pharma Advanced Research (NSE:SPARC) A Risky Investment?

Nov 23

If You Had Bought Sun Pharma Advanced Research's (NSE:SPARC) Shares Three Years Ago You Would Be Down 57%

Feb 08

Do Institutions Own Sun Pharma Advanced Research Company Limited (NSE:SPARC) Shares?

Dec 14

CEO

Anilkumar Raghavan (56 yo)

10.6yrs

Görev süresi

₹69,608,000

Tazminat

Mr. Anilkumar Raghavan has been the Chief Executive Officer of Sun Pharma Advanced Research Company Limited since April 24, 2014. Mr. Raghavan is a senior pharmaceutical services executive with significant...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Anilkumar Raghavan	Chief Executive Officer	10.6yrs	₹69.61m	Veri yok
Anup Rathi	Chief Financial Officer	less than a year	Veri yok	Veri yok
Nitin Dharmadhikari	Chief Operating Officer	less than a year	Veri yok	Veri yok
Jaydeep Issrani	Senior General Manager of Business Development	no data	Veri yok	Veri yok
Kajal Damania	Company Secretary & Compliance Officer	1.2yrs	Veri yok	Veri yok
Shanta Gupta	Chief Human Resource Officer	4.8yrs	Veri yok	Veri yok
Siu-Long Yao	Head Clinical Development	less than a year	Veri yok	Veri yok
Nitin Damle	Chief Innovation Officer	no data	Veri yok	Veri yok
Yashoraj Zala	Head of Drug Delivery Systems	no data	Veri yok	Veri yok
Vikram Ramanathan	Head of Preclinical Development	5.6yrs	Veri yok	Veri yok
Venkata Palle	Global Head of Drug Discovery & Preclinical Development	1.7yrs	Veri yok	Veri yok
Shravanti Bhowmik	VP & Head Operations Management	less than a year	Veri yok	Veri yok

1.2yrs

Ortalama Görev Süresi

Deneyimli Yönetim: SPARC 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.2 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Dilip Shanghvi	Chairman	18.7yrs	₹390.00k	19.06% ₹ 12.6b
Robert Jay Spiegel	Independent Director	4.4yrs	₹630.00k	Veri yok
Bhavna Doshi	Independent Director	10.1yrs	₹660.00k	Veri yok
Thennati Rajamannar	Non-Executive Non-Independent Director	17.4yrs	₹300.00k	0.011% ₹ 7.3m
Vidhi Shanghvi	Additional Non-Executive Non-Independent Director	less than a year	Veri yok	Veri yok
Ferzaan Engineer	Independent Director	7.5yrs	₹630.00k	Veri yok
Mark Simon	Member of Advisory Board	3.9yrs	₹570.00k	Veri yok

7.5yrs

Ortalama Görev Süresi

66yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: SPARC 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 7.5 yıldır).

Sun Pharma Advanced Research Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Sun Pharma Advanced Research Company Limited Appoints Vidhi Dilip Shanghvi as A Non- Executive, Non-Independent Director

Sun Pharma Advanced Research Company Limited Announces Re-Designation of Nitin Dharmadhikari as Chief Operating Officer

Sun Pharma Advanced Research Company Limited, Annual General Meeting, Aug 12, 2024

Sun Pharma Advanced Research Company Limited, Annual General Meeting, Aug 12, 2024

Sun Pharma Advanced Research Company Limited Announces Chief Financial Officer Changes

Insufficient new directors

Recent updates

New major risk - Negative shareholders equity

Second quarter 2025 earnings released: ₹3.31 loss per share (vs ₹2.66 loss in 2Q 2024)

New major risk - Revenue and earnings growth

Sun Pharma Advanced Research Company Limited to Report Q2, 2025 Results on Nov 04, 2024

Sun Pharma Advanced Research Company Limited Appoints Vidhi Dilip Shanghvi as A Non- Executive, Non-Independent Director

Sun Pharma Advanced Research Company Limited to Report Q1, 2025 Results on Aug 05, 2024

Sun Pharma Advanced Research Company Limited Announces Re-Designation of Nitin Dharmadhikari as Chief Operating Officer

Full year 2024 earnings released: ₹11.93 loss per share (vs ₹7.82 loss in FY 2023)

Sun Pharma Advanced Research Company Limited, Annual General Meeting, Aug 12, 2024

Sun Pharma Advanced Research Company Limited, Annual General Meeting, Aug 12, 2024

Sun Pharma Advanced Research Company Limited Announces Chief Financial Officer Changes

Sun Pharma Advanced Research Company Limited to Report Q4, 2024 Results on May 24, 2024

Third quarter 2024 earnings released: ₹3.07 loss per share (vs ₹0.37 profit in 3Q 2023)

Sun Pharma Advanced Research Company Limited to Report Q3, 2024 Results on Feb 05, 2024

Sun Pharma Advanced Research (NSE:SPARC) Is In A Good Position To Deliver On Growth Plans

Insufficient new directors

Sun Pharma Advanced Research Company Limited's (NSE:SPARC) Business Is Trailing The Industry But Its Shares Aren't

Second quarter 2024 earnings released: ₹2.66 loss per share (vs ₹2.52 loss in 2Q 2023)

Sun Pharma Advanced Research Company Limited Announces Retirement of Chitturi Trinadha Rao as Senior Vice President, Drug Discovery

Sun Pharma Advanced Research Company Limited to Report Q2, 2024 Results on Nov 06, 2023

Sun Pharma Advanced Research Company Limited Appoints Kajal Damania as Company Secretary

Sun Pharma Advanced Research Company Limited Announces the Resignation of Mr. Dinesh Lahoti as Company Secretary and Compliance Officer

Is Sun Pharma Advanced Research (NSE:SPARC) Using Too Much Debt?

Sun Pharma Advanced Research Company Limited to Report Q1, 2024 Results on Aug 07, 2023

Full year 2023 earnings released: ₹7.82 loss per share (vs ₹7.73 loss in FY 2022)

Sun Pharma Advanced Research Company Limited Announces That FDA Issues Complete Response Letter for Pdp-716 Nda Due to Inspection Findings At Third-Party Api Manufacturing Facility

Sun Pharma Advanced Research Company Limited, Annual General Meeting, Aug 07, 2023

Here's Why We're Not At All Concerned With Sun Pharma Advanced Research's (NSE:SPARC) Cash Burn Situation

Full year 2023 earnings released: ₹7.82 loss per share (vs ₹7.73 loss in FY 2022)

Sun Pharma Advanced Research Company Limited to Report Q4, 2023 Results on May 22, 2023

Third quarter 2023 earnings released: EPS: ₹0.37 (vs ₹0.60 loss in 3Q 2022)

Sun Pharma Advanced Research Company Limited to Report Q3, 2023 Results on Feb 13, 2023

Sun Pharmaceutical Industries Limited and Sun Pharma Advanced Research Company Limited Announces U.S. FDA Approval of SEZABY (Phenobarbital Sodium Powder for Injection) for the Treatment of Neonatal Seizures

Second quarter 2023 earnings released: ₹2.52 loss per share (vs ₹2.09 loss in 2Q 2022)

Sun Pharma Advanced Research Company Limited to Report Q2, 2023 Results on Nov 07, 2022

Sun Pharma Advanced Research Company Limited, Annual General Meeting, Sep 22, 2022

First quarter 2023 earnings released: ₹3.03 loss per share (vs ₹2.34 loss in 1Q 2022)

Sun Pharma Advanced Research Company Limited to Report Q1, 2023 Results on Aug 08, 2022

Full year 2022 earnings released: ₹7.73 loss per share (vs ₹5.77 loss in FY 2021)

Sun Pharma Advanced Research Company Limited to Report Q4, 2022 Results on May 17, 2022

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Is Sun Pharma Advanced Research (NSE:SPARC) A Risky Investment?

Second quarter 2022 earnings released: ₹2.09 loss per share (vs ₹3.19 loss in 2Q 2021)

Director Bhavna Doshi has joined 6th company board

Director Bhavna Doshi has joined 6th company board

Director Bhavna Doshi has joined 6th company board

Director Bhavna Doshi has joined 6th company board

Director Bhavna Doshi has joined 6th company board

Director Bhavna Doshi has joined 6th company board

Director Bhavna Doshi has joined 6th company board

Director Bhavna Doshi has joined 6th company board

Director Bhavna Doshi has joined 6th company board

First quarter 2022 earnings released: ₹2.34 loss per share (vs ₹2.16 profit in 1Q 2021)

Full year 2021 earnings released: ₹5.77 loss per share (vs ₹11.92 loss in FY 2020)

Sun Pharma Advanced Research Company Ltd. Reports Positive Top-Line Results from Its Phase 3 Trial for Its Investigational Drug

Sun Pharma Advanced Research Company Limited announced that it expects to receive INR 3.002424034 billion in funding from a group of investors

New 90-day low: ₹168

Sun Pharma Advanced Research Company Limited Announces the U.S. Food and Drug Administration Deny Appeal of the Complete Response Letter

Third quarter 2021 earnings released: ₹2.58 loss per share (vs ₹2.12 loss in 3Q 2020)

If You Had Bought Sun Pharma Advanced Research's (NSE:SPARC) Shares Three Years Ago You Would Be Down 57%

Sun Pharma Advanced Research Company Limited to Report Q3, 2021 Results on Feb 08, 2021

New 90-day high: ₹197

Do Institutions Own Sun Pharma Advanced Research Company Limited (NSE:SPARC) Shares?

New 90-day high: ₹185

Second quarter 2021 earnings released: ₹3.19 loss per share

Sun Pharma Advanced Research Company Limited to Report Q2, 2021 Results on Nov 09, 2020

New 90-day low: ₹165

Sun Pharma Advanced Research Company Limited Announces the Grant of an Exclusive License to Tripoint Therapeutics Llc, USA (Tripoint) to Commercialize Elepsia Xr 1000 Mg and Elepsia Xr 1500 Mg Tablets

New 90-day high - ₹190